Genes involved in innate immunity associated with asbestos-related fibrotic changes

Occupational and Environmental Medicine

Volumn 71, Issue 1, 2014, Pages 48-54

  Kukkonen, Mari K ^a   Vehmas, Tapio ^a   Piirilä, Päivi ^b   Hirvonen, Ari ^a  

^a FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; CRYOPYRIN; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR;

ADULT; ALLELE; ARTICLE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; PLEURA PLAQUE; PLEURA THICKENING; PLEURAL FIBROSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

AGED; ALLELES; ASBESTOS; CARD SIGNALING ADAPTOR PROTEINS; CARRIER PROTEINS; FEMALE; FIBROSIS; FINLAND; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; IMMUNITY, INNATE; LUNG; LUNG DISEASES; MALE; MIDDLE AGED; NEOPLASM PROTEINS; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; OCCUPATIONS; PEPTIDE HYDROLASES; PLEURAL DISEASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEASE INHIBITORS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84890118332     PISSN: 13510711     EISSN: 14707926     Source Type: Journal    
DOI: 10.1136/oemed-2013-101555     Document Type: Article

References (46)

1. Virta R. Worldwide Asbestos Supply and Consumption Trends from 1900 through 2003. US Geological Survey (Circular 1298). 2006. http://pubs.usgs.gov/ circ/2006/1298/c1298.pdf
2. Ban Asbestos Secretariat. http://ibasecretariat.org
3. Kamp DW. Asbestos-induced lung diseases: an update. Transl Res 2009;153:143-52.
4. World Health Organization. 2010. Asbestos: elimination of asbestos-related diseases. WHO Media Centre. Fact sheet No343. http://www.who.int/mediacentre/factsheets/fs343/en/index.html
5. Diandini R, Takahashi K, Park EK, et al. Potential years of life lost (PYLL) caused by asbestos-related diseases in the world. Am J Ind Med 2013;56:993-1000.
6. Liu G, Cheresh P, Kamp DW. Molecular basis of asbestos-induced lung disease. Annu Rev Pathol 2013;8:161-87.
7. Mossman BT, Gee JB. Asbestos-related diseases. N Engl J Med 1989;320:1721-30.
8. Lagente V, Manoury B, Nenan S, et al. Role of matrix metalloproteinases in the development of airway in flammation and remodeling. Braz J Med Biol Res 2005;38:1521-30.
9. Tan RJ, Fattman CL, Niehouse LM, et al. Matrix metalloproteinases promote inflammation and fibrosis in asbestos-induced lung injury in mice. Am J Respir Cell Mol Biol 2006;35:289-97.
10. Zhang Y, Lee TC, Guillemin B, et al. Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J Immunol 1993;150:4188-96.
11. Sullivan DE, Ferris M, Pociask D, et al. The latent form of TGFbeta(1) is induced by TNFalpha through an ERK specific pathway and is activated by asbestos-derived reactive oxygen species in vitro and in vivo. J Immunotoxicol 2008;5:145-9.
12. Bartram U, Speer CP. The role of transforming growth factor beta in lung development and disease. Chest 2004;125:754-65.
13. Nishimura Y, Nishiike-Wada T, Wada Y, et al. Long-lasting production of TGF-beta1 by alveolar macrophages exposed to low doses of asbestos without apoptosis. Int J Immunopathol Pharmacol 2007;20:661-71.
14. Helmig S, Aliahmadi N, Schneider J. Tumour necrosis factor-alpha gene polymorphisms in asbestos-induced diseases. Biomarkers 2010;15:400-9.
15. Helmig S, Belwe A, Schneider J. Association of transforming growth factor beta1 gene polymorphisms and asbestos-induced fibrosis and tumors. J Investig Med 2009;57:655-61.
16. Yaguchi T, Fukuda Y, Ishizaki M, et al. Immunohistochemical and gelatin zymography studies for matrix metalloproteinases in bleomycin-induced pulmonary fibrosis. Pathol Int 1998;48:954-63.
17. Swaisgood CM, French EL, Noga C, et al. The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. Am J Pathol 2000;157:177-87.
18. Dostert C, Petrilli V, Van Bruggen R, et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008;320:674 -7.
19. Verma D, Lerm M, Blomgran Julinder R, et al. Gene polymorphisms in the NALP3 inflammasome are associated with interleukin-1 production and severe inflammation: relation to common inflammatory diseases? Arthritis Rheum 2008;58:888-94.
20. Cassel SL, Eisenbarth SC, Iyer SS, et al. The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci U S A 2008;105:9035-40.
21. Yamamoto N, Homma S. Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci U S A 1991;88:8539-43.
22. Chishimba L, Thickett DR, Stockley RA, et al. The vitamin D axis in the lung: a key role for vitamin D-binding protein. Thorax 2010;65:456-62.
23. Koskinen K, Rinne JP, Zitting A, et al. Screening for asbestos-induced diseases in Finland. Am J Ind Med 1996;30:241 -51.
24. Koskinen K, Zitting A, Tossavainen A, et al. Radiographic abnormalities among Finnish construction, shipyard and asbestos industry workers. Scand J Work Environ Health 1998;24:109-17.
25. Huuskonen O, Kivisaari L, Zitting A, et al. High-resolution computed tomography classification of lung fibrosis for patients with asbestos-related disease. Scand J Work Environ Health 2001;27:106 -12.
26. Tiitola M, Kivisaari L, Zitting A, et al. Computed tomography of asbestos-related pleural abnormalities. Int Arch Occup Environ Health 2002;75:224-8.
27. Vierikko T, Jarvenpaa R, Autti T, et al. Chest CT screening of asbestos-exposed workers: lung lesions and incidental findings. Eur Respir J 2007;29:78-84.
28. Koskinen K, Pukkala E, Martikainen R, et al. Different measures of asbestos exposure in estimating risk of lung cancer and mesothelioma among construction workers. J Occup Environ Med 2002;44:1190 -6.
29. Jaakkola MS, Piipari R, Jaakkola N, et al. Environmental tobacco smoke and adult-onset asthma: a population-based incident case-control study. Am J Public Health 2003;93:2055-60.
30. Gevenois PA, de Maertelaer V, Madani A, et al. Asbestosis, pleural plaques and diffuse pleural thickening: three distinct benign responses to asbestos exposure. Eur Respir J 1998;11:1021-7.
31. Piirilä P, Kivisaari L, Huuskonen O, et al. Association of findings in flow-volume spirometry with high-resolution computed tomography signs in asbestos-exposed male workers. Clin Physiol Funct Imaging 2009;29:1 -9.
32. Andreassen CN, Alsner J, Overgaard J, et al. TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol 2005;75:18-21.
33. Joos L, He JQ, Shepherdson MB, et al. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet 2002;11:569-76.
34. Ozen S, Alikasifoglu M, Bakkaloglu A, et al. Tumour necrosis factor alpha G→A -238 and G→A -308 polymorphisms in juvenile idiopathic arthritis. Rheumatology 2002;41:223-7.
35. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
36. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73:1162-9.
37. Artlett CM. The role of the NLRP3 inflammasome in fibrosis. Open Rheumatol J 2012;6:80-6.
38. dos Santos G, Kutuzov MA, Ridge KM. The inflammasome in lung diseases. Am J Physiol Lung Cell Mol Physiol 2012;303:L627-633.
39. Verma D, Sarndahl E, Andersson H, et al. The Q705K polymorphism in NLRP3 is a gain-of-function alteration leading to excessive interleukin-1beta and IL-18 production. PLoS One 2012;7:e34977.
40. Ji X, Hou Z, Wang T, et al. Polymorphisms in inflammasome genes and risk of coal workers' pneumoconiosis in a Chinese population. PLoS One 2012;7:e47949.
41. McCunney RJ, Morfeld P, Payne S. What component of coal causes coal workers' pneumoconiosis? J Occup Environ Med 2009;51:462-71.
42. Dunning AM, Ellis PD, McBride S, et al. A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 2003;63:2610-15.
43. Yokota M, Ichihara S, Lin TL, et al. Association of a T29→C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000;101:2783-7.
44. Lee PH, Shatkay H. F-SNP: computationally predicted functional SNPs for disease association studies. Nucleic Acids Res 2008;36:D820-4.
45. Johnson JL, Baker AH, Oka K, et al. Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: involvement of macrophage migration and apoptosis. Circulation 2006;113:2435-44.
46. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43-6.